Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00539383 · ClinicalTrials.gov registry record · Phase 1
A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Advanced Solid Tumors and Metastatic Brain Cancer
A Phase 1 study of Advanced Solid Tumors With and Without Brain Metastases, sponsored by Angiochem.
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
- 3
- Study locations
NCT00539383 is a Phase 1 study of Advanced Solid Tumors With and Without Brain Metastases that has completed, run by Angiochem. The registered enrollment target is 56 participants. The trial reports 3 study locations across 2 states.
The verdict
NCT00539383, a Phase 1 study of Advanced Solid Tumors With and Without Brain Metastases, has completed, sponsored by Angiochem.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a phase 1, multi-centre, sequential cohort, open-label, dose-escalation study of the safety, tolerability, and PK of ANG1005 in patients with solid tumors (with or without brain metastases). ANG1005 will be given by IV infusion once every 21 days (1 treatment cycle). Each patient will participate in only 1 dose group and will receive up to 6 cycles of treatment provided there is no evidence of tumor progression, there is recovery to ≤Grade 1 or baseline nonhematologic, ANG1005-related toxicity (except alopecia), the absolute neutrophil count is ≥1.5 x 109/L, and the platelet count is ≥100 x 109/L.
Conditions Studied
Interventions
- DRUG ANG1005
Study Locations (3)
Texas
- University of Texas, MD Anderson Cancer Center - Houston
- UT Health Science Center, Cancer Therapy and Research Center - San Antonio
Ohio
- Gabrail Cancer Center - Canton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2007-10 |
| Est. Completion | 2010-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00539383
The ClinicalTrials.gov registry entry for NCT00539383 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Angiochem, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Solid Tumors With and Without Brain Metastases appearing as the primary indexed condition, and to 1 intervention - of which ANG1005 is the first listed.
NCT00539383 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Texas, Ohio.
Frequently Asked Questions
What is clinical trial NCT00539383 about?
NCT00539383 is a clinical study titled "A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Advanced Solid Tumors and Metastatic Brain Cancer". This is a phase 1, multi-centre, sequential cohort, open-label, dose-escalation study of the safety, tolerability, and PK of ANG1005 in patients with solid tumors (with or without brain metastases). ANG1005 will be given by IV infusion once every 21 days (1 treatment cycle). Each patient will partic...
What is the current status of trial NCT00539383?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2007-10. Estimated completion is 2010-03.
What conditions does trial NCT00539383 study?
This clinical trial studies the following conditions: Advanced Solid Tumors With and Without Brain Metastases.
What interventions are being tested in trial NCT00539383?
The interventions under investigation include: ANG1005 (DRUG).
Who is sponsoring clinical trial NCT00539383?
This trial is sponsored by Angiochem, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00539383 being conducted?
This trial has 3 study locations across Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.